newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second ha